Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: A preliminary report

Drugs in R and D

Volumn 4, Issue 2, 2003, Pages 91-101

  Burzynski, Stanislaw R ^a   Lewy, Robert I ^a   Weaver, Robert A ^a   Axler, Maxwell L ^a   Janicki, Tomasz J ^a   Jurida, Gabor F ^a   Paszkowiak, Jaroslaw K ^a   Szymkowski, Barbara G ^a   Khan, Mohammad I ^a   Bestak, Mark ^a  

^a Burzynski Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ANTINEOPLASTON AS2-1; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; GADOLINIUM; GLUTAMINE DERIVATIVE; NITROSOUREA DERIVATIVE; PHENYLACETIC ACID DERIVATIVE; VINCRISTINE;

ADULT; AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; BRAIN STEM TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GLIOMA; HOSPITAL ADMISSION; HUMAN; HYPERNATREMIA; HYPOGLYCEMIA; MALE; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN ALLERGY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENEACETAMIDES; BRAIN STEM NEOPLASMS; CEREBRAL ANGIOGRAPHY; CHILD; DRUG COMBINATIONS; GLIOMA; GLUTAMINE; HUMANS; KARNOFSKY PERFORMANCE STATUS; PHENYLACETATES; PIPERIDONES; RISK ASSESSMENT; TIME FACTORS;

EID: 0042357080     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304020-00002     Document Type: Article

References (41)

1. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futramed Publishers, 1992: 2506-7
2. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 1998; 40: 265-71
3. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51
4. Adam L, Crépin M, Savin C, et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7 ras cells in vitro and in nude mice. Cancer Res 1995; 55: 5156-60
5. Samid D, Shack S, Sherman LT. Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988-92
6. Shack S, Chen LC, Miller AC, et al. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer 1995; 63: 124-9
7. DiCroce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-82
8. Gorospe M, Shack S, Guyton KZ, et al. Up-regulation and functional role of p21WAF1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 1996; 7: 1609-15
9. Liu L, Samid D. Mutant p53 as a target of phenylacetate in human glioblastoma [abstract 2580]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research, Toronto, Canada; AACR 1995, 433 433
10. Kamitani H, Tanjura S, Watanbe K, et al. Histone acetylation may suppress human glioma cell proliferation with p21WAF1/Cip1 and gelsolin are induced. Neuro-Oncol 2002; 4: 95-101
11. Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exp Clin Res 1986; 12 (Suppl 1): 11-6
12. Ram Z, Samid D, Waldbridge S, et al. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 1994; 54: 2923-7
13. Stockhammer G, Manley GT, Johnson R, et al. Inhibition of proliferation and induction of differentiation in medullo-blastoma-and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 1995; 83: 672-81
14. Liu L, Shack S, Stetler-Stevenson WG, et al. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 1994; 103: 355-40
15. Danesi R, Nardini D, Basolo F, et al. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 1996; 49: 972-9
16. Sidell N, Wada R, Han G, et al. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuro-blastoma cells. Int J Cancer 1995; 60: 507-14
17. Cinatl J, Cinatl JA, Herneiz P, et al. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett 1994; 78: 41-8
18. Ferrandina G, Melichar B, Loercher A, et al. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 1997; 57: 4309-15
19. Samid D, Yeh A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 1992; 809: 1576-81
20. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990; 16: 361-9
21. Liau MC, Liau CP, Burzynski SR. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Int J Exp Clin Chemother 1992; 5: 9-17
22. Tsuda H, Hara H, Eriguchi N, et al. Inhibitory effect of antineoplaston A10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. Kurume Med J 1990; 37: 97-104
23. Wood JC, Copland JA, Muldoon TG, et al. 3-phenylacetylamino-2, 6-piperidinedione inhibition of rat Nb2 lymphoma cell mitogenesis. Proc Soc Exp Biol Med 1991; 197: 404-8
24. Xu W, Yu R, Gao C, et al. The preliminary antitumor assay of antineoplaston A10 against the s180 and the effects of cAMP levels in tumor and liver tissues of mice. Adv Exp Clin Chemother 1988; 2: 41-4
25. Hashimoto K, Koga T, Shintomi Y, et al. The anticancer effect of antineoplaston A10 on human breast cancer serially transplanted to athymic mice. Nippon Gan Chiryo Gakkai Shi 1990; 25: 1-5
26. Burzynski SR. Purified antineoplaston fractions and methods of treating neoplastic disease. US patent 4,470,970. 1984
27. Burzynski SR. Phase I clinical studies of antineoplaston AS2-5 injections. In: Ishigami J, editor. Recent advances in chemotherapy. Tokyo: University of Tokyo Press, 1985: 586-7
28. Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995; 7: 157-67
29. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Report. J Clin Oncol 1999; 17: 984-90
30. Buckner JD, Malkin MG, Reed E, et al. Phase II study of antineoplaston A10 (NSC 648539) and AS2-1 (NSC 6200261) in patients with recurrent glioma. Mayo Clin Proc 1999; 74: 137-45
31. Burzynski SR. Efficacy of antineoplastons A10 and AS2-1. Mayo Clin Proc 1999; 74: 641-2
32. Fulton DS, Levin VA, Wara WM, et al. Chemotherapy of pediatric brain-stem tumors. J Neurosurg 1981; 54: 721-5
33. Rodriguez LA, Prados M, Fulton D, et al. Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. Neurosurgery 1988; 23: 691-3
34. Allen JC, Hancock C, Walker R, et al. PCNU and recurrent childhood brain tumors. J Neurooncol 1987; 5: 241-4
35. van Eys J, Baram TZ, Cangir A, et al. Salvage chemotherapy for recurrent primary brain tumors in children. J Pediatr 1988; 113: 601-6
36. Prados M, Rodriguez L, Chamberlain M, et al. Treatment of recurrent gliomas with 1, 3-bis(2-chlorethyl)-1-nitrosourea and α-fluromethylornithine. Neurosurgery 1989; 24: 806-9
37. Heideman RL, Packer RJ, Reaman GH, et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993; 72: 271-5
38. Corden BJ, Strauss LC, Killmond T, et al. Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neurooncol 1991; 11: 57-63
39. Pendergrass TW, Milstein JM, Geyer JR, et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 1987; 5: 1221-31
40. Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of pediatric oncology group phase III trial comparing conventional vs hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43: 959-64
41. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the children's cancer group. J Clin Oncol 2002; 20 (16): 3431-7